List of Excipients in Branded Drug KERANIQUE HAIR REGROWTH TREATMENT FOR WOMEN

« Back to Dashboard

Generic Drugs Containing KERANIQUE HAIR REGROWTH TREATMENT FOR WOMEN

Company	Ingredient	NDC	Excipient
Pure Source LLC	minoxidil 2%	65121-578	ISOPROPYL ALCOHOL
Pure Source LLC	minoxidil 2%	65121-578	PROPYLENE GLYCOL
Pure Source LLC	minoxidil 2%	65121-578	WATER
PROFECTUS BEAUTY LLC	minoxidil	70550-578	ALCOHOL

What are the Most Frequently-Used Excipients in KERANIQUE HAIR REGROWTH TREATMENT FOR WOMEN?

# Of NDCs	Excipient
1	ALCOHOL
1	ISOPROPYL ALCOHOL
2	PROPYLENE GLYCOL
2	WATER

Keranique Hair Regrowth Treatment for Women: Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Keranique Hair Regrowth Treatment for Women is an over-the-counter topical minoxidil product positioned for female pattern hair loss. The core product is a 2% minoxidil topical solution. Its excipient system is conventional and commercially replaceable: alcohol, propylene glycol, purified water, and formulation components that support solubility, spreading, evaporation, and scalp penetration. The largest opportunities are improved tolerability, reduced residue, better dose delivery, and line extensions rather than new active-ingredient exclusivity.

What is Keranique Hair Regrowth Treatment for Women?

Keranique Hair Regrowth Treatment is marketed as a topical treatment for female pattern hair loss associated with gradual thinning on the top of the scalp. The active ingredient in the women's treatment is minoxidil 2% w/v, applied directly to the scalp according to the product labeling.[1]

Attribute	Commercial profile
Brand	Keranique
Active ingredient	Minoxidil 2%
Dosage form	Topical scalp solution
Therapeutic category	OTC hair regrowth treatment
Target population	Women with gradual hair thinning
Primary indication	Female pattern hair loss
Route	Topical
Regulatory pathway	OTC drug product
Principal formulation challenge	Minoxidil solubility and scalp tolerability
Primary commercial barrier	Low-cost generic minoxidil competition

Keranique is sold as part of a broader hair-care system that can include shampoo, conditioner, scalp products, and treatment kits. This creates a commercial platform around the regulated minoxidil product, even though the active drug itself is an established generic ingredient.

What excipients are used in Keranique minoxidil treatment?

The standard 2% minoxidil solution uses a hydroalcoholic vehicle. The principal excipients are generally alcohol, propylene glycol, and purified water. Exact inactive-ingredient quantities can vary by product configuration and label version.

Excipient or vehicle component	Primary function	Commercial relevance
Alcohol, commonly ethanol	Solvent, rapid evaporation, scalp drying	Can increase stinging, dryness, and flammability concerns
Propylene glycol	Cosolvent and humectant; improves minoxidil solubility	Can cause irritation or allergic contact dermatitis in some users
Purified water	Diluent and vehicle component	Supports acceptable feel and manufacturing control
Packaging system	Protects volatile solvent system	Important for evaporation, leakage, dosing, and stability

Minoxidil has limited water solubility. A hydroalcoholic system with propylene glycol allows the drug to remain dissolved at the labeled concentration. The same excipients that enable solubility can create the principal consumer complaints: scalp irritation, dryness, tackiness, odor, and visible residue.

The formulation strategy is therefore a balance between four requirements:

1. Keep minoxidil dissolved during shelf life.
2. Deliver a reproducible amount to the scalp.
3. Allow rapid spreading and drying.
4. Minimize irritation during repeated use.

How strong is the formulation strategy for Keranique?

The existing formulation is technically adequate but weakly differentiated. It relies on widely used excipients and does not create a meaningful barrier against competing products. Minoxidil 2% solutions are available from numerous manufacturers, and comparable solvent systems are common in OTC hair-loss products.

The formulation's strengths are low manufacturing complexity, established raw-material supply, and a familiar regulatory profile. Its weaknesses are limited sensory differentiation and the potential for propylene glycol or alcohol intolerance.

Technical strengths

• Minoxidil is fully incorporated in a familiar solvent system.
• Liquid application supports direct scalp dosing.
• The ingredients are inexpensive and widely available.
• The product can be manufactured at standard nonsterile topical facilities.
• The system is compatible with bottles, droppers, and metered applicators.

Technical weaknesses

• Propylene glycol may cause itching, burning, scaling, or contact dermatitis.
• Alcohol can increase scalp dryness and stinging.
• Liquid products can run from the scalp or affect hair styling.
• Evaporation can change the concentration or sensory profile if the closure is inadequate.
• The product is vulnerable to substitution by lower-priced store-brand minoxidil.

The current excipient system is best viewed as a cost-efficient baseline, not as a defensible proprietary platform.

What formulation patents protect Keranique minoxidil treatment?

No meaningful patent barrier is apparent from the conventional minoxidil solution composition. Minoxidil was discovered decades ago, and basic topical solutions containing minoxidil, alcohol, propylene glycol, and water are unlikely to support strong current composition-of-matter protection.

Patent protection profile

Protection category	Likely position
Minoxidil active ingredient	Expired or unavailable as new-molecule protection
Basic 2% topical solution	Commodity formulation; limited patent value
Alcohol/propylene glycol vehicle	Established excipient combination
Packaging	Potentially protectable only if structurally novel
Metered delivery	Possible device or combination claims
Cosmetic adjuncts	Potential formulation or branding differentiation
Method of use	Limited value where the use is covered by established OTC labeling
Manufacturing process	Potentially protectable if process-specific and nonobvious

The commercial value is therefore more likely to come from trademarks, trade dress, customer acquisition, subscriptions, retail placement, and bundled products than from drug patents.

A patent search should distinguish Keranique's brand ownership from the entity that manufactures or distributes the drug. A brand owner may not own relevant formulation patents. Patent records should be checked by product manufacturer, distributor, assignee, and affiliated companies rather than by the brand name alone.

What is the FDA regulatory status of Keranique?

Keranique's minoxidil treatment is positioned as an OTC drug product. Topical minoxidil products are regulated through the FDA's OTC framework and product-specific labeling requirements rather than through a conventional new drug approval strategy for each branded product.[2]

The key regulatory controls include:

• Active ingredient concentration.
• Indication for gradual hair loss.
• Directions for use.
• Contraindications and warnings.
• Inactive-ingredient disclosure.
• Container and closure suitability.
• Stability and quality testing.
• Manufacturing under current good manufacturing practice requirements.

A branded OTC product can compete without owning an approved new drug application if it conforms to the applicable OTC regulatory framework. This lowers entry barriers for generic and private-label manufacturers.

Does Keranique have Orange Book protection?

Keranique's topical minoxidil product should not be treated as an Orange Book-protected branded prescription product. The Orange Book is primarily relevant to approved new drug applications and listed patents for qualifying prescription and certain approved nonprescription products.[3]

For a conventional OTC minoxidil product:

• Orange Book patent listings are unlikely to create a practical exclusivity barrier.
• Paragraph IV litigation is not the main generic-entry mechanism.
• Competitors can enter through their own compliant OTC products.
• FDA labeling, manufacturing quality, and distribution execution matter more than listed-patent status.

The absence of a meaningful Orange Book estate does not eliminate regulatory risk. A company can still face FDA action, product recalls, manufacturing observations, label disputes, trademark litigation, or retailer delisting.

When does Keranique lose exclusivity?

Keranique does not have conventional new-drug exclusivity for the basic minoxidil active ingredient. Competitive entry is already available through generic and private-label topical minoxidil products.

The relevant commercial timeline is therefore not a patent-expiration date. It is the timing of:

• Product launches by competing OTC manufacturers.
• Retailer acceptance of lower-priced alternatives.
• Changes in minoxidil formulation preferences.
• Consumer migration to 5% foam or once-daily products.
• Growth of telehealth and subscription hair-loss services.
• Launches of cosmetic scalp serums positioned around minoxidil use.

Any protection is mainly brand-based. A formulation improvement could generate new patent or regulatory value only if it introduces a genuinely novel delivery system, composition, device, or manufacturing method.

What excipient opportunities exist for Keranique?

The strongest opportunities are in tolerability and delivery. A successful reformulation must preserve minoxidil solubility while reducing alcohol and propylene glycol exposure or improving the user experience.

1. Propylene glycol reduction or replacement

Propylene glycol is effective but can be poorly tolerated. Potential alternatives include:

• Transcutol-type solvents.
• Polyethylene glycol systems.
• Diethylene glycol monoethyl ether derivatives.
• Glycerol-based cosolvent systems.
• Glycol ethers selected for topical safety and scalp feel.
• Solubilizing surfactant systems at low concentrations.

The principal development issue is maintaining minoxidil solubility through the full temperature range without crystallization. Replacing propylene glycol may improve tolerability but can create new risks involving precipitation, oily feel, penetration changes, or scalp irritation.

2. Lower-alcohol or alcohol-free liquid systems

An alcohol-reduced formula could address dryness and stinging. Candidate approaches include:

• Water-rich cosolvent systems.
• Polyol-based vehicles.
• Mild solubilizer combinations.
• Emulsion or microemulsion platforms.
• Structured aqueous gels.

A lower-alcohol product may have slower drying, increased residue, and lower consumer acceptance unless the application system is redesigned.

3. Foam and mousse systems

Foam provides a major commercial opportunity because it can reduce dripping and improve application control. It can also change the sensory profile and lower perceived residue.

A foam platform may support:

• Faster scalp application.
• Better use on longer hair.
• Lower visible wetness.
• Improved portability.
• Premium pricing.
• Once-daily or simplified regimens, subject to regulatory support.

Foam technology introduces packaging complexity. The company must control propellant compatibility, valve performance, dose uniformity, flammability labeling, and stability.

4. Hydrogel and film-forming systems

A scalp hydrogel could improve residence time and reduce runoff. Film-forming polymers may help keep minoxidil at the application site, but excessive film formation can cause flaking or make hair feel stiff.

Useful development targets include:

• Low-tack polymers.
• Nonflaking film formers.
• Fast-drying gels.
• Rheology systems that prevent dripping.
• Polymers compatible with minoxidil solubility.

This strategy is more likely to produce defensible formulation IP than a simple excipient substitution.

5. Scalp-conditioning excipients

A treatment designed for repeated use could incorporate compatible conditioning ingredients, provided they do not impair minoxidil stability or create regulatory complications.

Potential ingredients include:

• Panthenol.
• Allantoin.
• Betaine.
• Low-irritancy humectants.
• Mild scalp-conditioning polymers.
• Selected botanical extracts with cosmetic positioning.

These ingredients can improve consumer perception but generally provide weaker patent protection than a novel delivery system. Botanical claims also require careful substantiation and separation between cosmetic claims and drug claims.

What manufacturing and IP barriers affect reformulation?

The principal manufacturing challenge is not minoxidil synthesis. It is reproducible solubilization and filling of a volatile topical system.

Manufacturing considerations

• Control of solvent composition during compounding.
• Prevention of minoxidil crystallization.
• Homogeneous mixing at commercial scale.
• Container-closure compatibility.
• Evaporation loss during filling.
• Dose reproducibility from dropper or pump systems.
• Stability under heat and freeze-thaw stress.
• Microbial control in water-containing systems.
• Compatibility with labels, liners, and plastics.

A new formulation can create patent opportunities around solvent ratios, crystallization control, particle size, delivery devices, or multi-phase systems. The claims must be drafted around measurable technical effects, not a list of familiar excipients.

Which companies challenge Keranique commercially?

Keranique competes with branded and private-label minoxidil products, including:

Competitor group	Competitive advantage
Rogaine	Strong consumer recognition and broad distribution
Store-brand minoxidil	Low price and retailer control
Generic pharmaceutical manufacturers	Scale and low manufacturing cost
5% foam brands	Convenience and premium positioning
Telehealth hair-loss companies	Subscription conversion and clinical engagement
Cosmetic scalp-care brands	Sensory experience and lifestyle branding
Oral hair-loss services	Convenience, though with different safety and regulatory profiles

The most direct threat is not a Paragraph IV challenger. It is substitution by an equivalent topical minoxidil product with lower price or better application characteristics.

What licensing deals could create commercial value?

Licensing opportunities are strongest in formulation technology and delivery devices. Relevant targets include:

• Propylene glycol-free minoxidil vehicles.
• Low-alcohol formulations.
• Metered-dose applicators.
• Foam and aerosol platforms.
• Microemulsion systems.
• Scalp-retention polymers.
• Stability-enhancing solubilizer systems.
• Combination products with cosmetic scalp-care ingredients.

A licensing agreement should separate rights for the active drug, formulation, device, manufacturing process, and consumer brand. The most valuable deal structure would likely combine a formulation license with manufacturing transfer and territorial exclusivity.

A basic excipient license has limited value unless it delivers a measurable commercial benefit, such as improved adherence, reduced irritation, longer shelf life, or a lower-cost package.

What generic launch risks exist for Keranique?

Generic entry risk is high because the product uses an established active ingredient and a conventional dosage form. A competitor can attack market share through five routes:

1. Lower retail pricing.
2. Higher-strength minoxidil positioning.
3. Foam or pump delivery.
4. Subscription replenishment.
5. Bundling with shampoo, supplements, or telehealth services.

Keranique can reduce substitution risk by making the full regimen more convenient and by improving the treatment experience. Brand loyalty alone is less durable when the active ingredient and use case are familiar to consumers.

How does Keranique compare with 5% minoxidil products?

Attribute	Keranique 2% solution	Typical 5% foam or solution
Active concentration	2%	5%
Application burden	Often twice daily under traditional labeling	Often once daily for women, depending on product labeling
Vehicle	Hydroalcoholic liquid	Foam or liquid
Dripping risk	Higher	Lower with foam
Residue	Can be noticeable	Often lower with foam
Price positioning	Mid-market or premium branded OTC	Broad range
Differentiation	Brand and regimen	Strength, convenience, delivery
Main consumer concern	Irritation and inconvenience	Irritation, cost, and adherence

The 5% segment has stronger convenience positioning, but the 2% product can retain a role for consumers who prefer lower concentration, liquid application, or a specific branded regimen.

What revenue exposure does the excipient strategy create?

Revenue exposure is concentrated in repeat use. Hair-regrowth products require sustained application, making refill frequency, adherence, and subscription retention more important than one-time trial purchases.

A successful excipient reformulation could improve revenue through:

• Higher repeat-purchase rates.
• Lower discontinuation from irritation.
• Premium pricing for foam or serum formats.
• Expanded retail placement.
• Bundling with Keranique hair-care products.
• Subscription programs.
• Professional-channel distribution.
• International variants adapted to local regulatory requirements.

The economic risk is that reformulation raises cost without creating a visible benefit. Consumers may not pay more for an invisible excipient change. The improvement must be communicated through a clear product attribute such as "non-greasy," "fast-drying," "no-drip," or "sensitive-scalp formula," subject to substantiation and labeling review.

Key Takeaways

• Keranique Hair Regrowth Treatment for Women is an OTC 2% minoxidil topical solution.
• Its conventional alcohol, propylene glycol, and water vehicle is effective but weakly differentiated.
• Basic minoxidil composition patents do not provide a meaningful current barrier to generic competition.
• Orange Book and Paragraph IV issues are less important than OTC compliance, pricing, and brand execution.
• The strongest excipient opportunities are propylene glycol reduction, alcohol reduction, foam delivery, hydrogel systems, and improved scalp residence.
• New IP is more plausible around delivery devices, solvent systems, crystallization control, and measurable tolerability improvements.
• The principal commercial threat is substitution by low-cost generics and better-convenience 5% products.
• A reformulation should be paired with packaging, dosing, subscription, and regimen strategies to create commercial value.

FAQs

Can Keranique use a propylene glycol-free formulation?

Yes. A propylene glycol-free product is technically feasible, but the replacement vehicle must maintain minoxidil solubility, stability, dose uniformity, and acceptable scalp feel.

Would a new Keranique foam receive new drug exclusivity?

Not automatically. A new foam may qualify for patent protection if the formulation or device is novel and nonobvious, but reformulation alone does not guarantee regulatory exclusivity.

Is minoxidil solubility the main excipient development problem?

Yes. The vehicle must keep minoxidil dissolved during manufacturing, storage, and application. Removing propylene glycol or reducing alcohol can increase precipitation risk.

Can Keranique patent a metered-dose applicator?

Potentially. Patentability would depend on the structure, dosing mechanism, and technical performance of the applicator. The strongest claims would cover a novel combination of device and minoxidil formulation.

Does a Keranique shampoo formulation compete directly with the minoxidil treatment?

No. Shampoo and conditioner products support the brand and regimen but are not direct substitutes for the minoxidil drug treatment. They can increase basket size and retention while carrying separate cosmetic formulation and trademark opportunities.

References

1. Keranique. (n.d.). Hair regrowth treatment for women: Drug facts labeling. Keranique.

2. U.S. Food and Drug Administration. (n.d.). Minoxidil topical drug products and over-the-counter hair-loss treatment requirements. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2023). Current good manufacturing practice requirements for drugs. FDA.